to quarter, second showcasing are in platforms. our our the In business Mark. alternative efforts sector protein bear microbial you, Thank continuing development potential of the the fruit,
protein have to of identifying commercialized. can we producing strategy As be near-term products efficiently concentrated high-volume high-value, revenue and on our and part quickly recombinant drive that
numerous prospects unlocking market. commercialization diverse serum single product serum $X for partnership combat This announced albumin various a segments. billion opportunities approximately within recently albumin the is Our prime example across offers
in crucial treatment serves vaccine has role plays For research a potential as development protein for in a development. and instance, as grade is disease carrier pharmaceutical reagent a a serum therapeutics albumin and standard
recombinant in of and products. for potentially bovine cell grown meat. completion for the commercialization muscle certificates for analytical cells cell media, them human valuable for albumin gene a culture is reset The [indiscernible] viable commercialize in albumin recombinant currently equivalents R&D. recent to processing and Additionally, making of and confirms lab particularly analysis diagnostics,
culture completed a also third-party cell as have our bovine of We media. recombinant microbial albumin produced of component through platforms
effectiveness This potential partnership its in recombinant and growing a culture and on market. recombinant [indiscernible], initially comparable ] focus potential for diagnostic, to of the of expected half culture nutrition unlock in rapidly argument global Health [ purified strategic the cells customer animal-derived product this Biologics, further the Proliant supplier with validating development a market in muscle have we to the cell proteins serum bringing XXXX. of launch human the To and first rolivinabumin base. leading Demonstrated products, a albumin collaboration markets expanding with first our its commercialization executed of with will
a the this or payment transfer will and following testing and product milestone and We've the milestone following quarter of $XXX,XXX Dyadic payment payment early portion generated of filamentous platforms. scale-up start by already validation will microbial efforts ProLiant of fourth and we support terms successful the from $XXX,XXX payment scale-up fungal payment using and products to we $X.X revenue validation. total profits fourth in a A second share final anticipate million, Dyadic a the in commercialization agreement, received XXXX sale quarter our technology the Under albumin recurring receiving receive the expect of projected upon year. upfront of from late recombinant made for the of animal-free expect the the third
product this RNA commercial partners to We're at in DNA to projected sector, completed and market actively scope accelerate applications. XXXX a its We've over $XXX million working of we the analytical a certificate ligases nonfood at to within the from of are XXXX, products. of Recently, to polymerases. DNAs, the in CAGR for particularly that's XXXX. issuance begun global of confirms the customers protein market development for commercialization of and valued and grow analysis XX.XX% the aggressively seeking sampling and comparability alternative opportunities existing and broaden its
cell market productivity at valued key of Over web significantly today Transferrin in transferrin]. from $X.XX at XX% to grow a of growers culture in growth Dyadic. annual attractive than strain to XXXX by the produced interest particularly cell the comprising the from In and costs. used cell is and addition, at culture and recombinant Notably, XX.XX% majority driven media was high transfer billion developed is more global transfer XX% with media, cell XXXX. expected [ recombinantly, media XXXX of rate component culture proteins of albumin it a compound we've of product for which media and is a recombinant the making culture and global in serum-free
efforts animal-free such presence animal-free intolerance associated evolving to cow media, microbial in possible. by concerns potential A third testing The with fermentation opportunities. products cell Our reach valued we've dairy goal global expedite cell via $XX lactose allergies. also expand the over in quarter precision as rapid In more produced sampling begin to issues for to is our products, culture net by are products products earn other milk, the traditional technology. for consumer than was a health Dyadic commercialization cost-reducing at application XXXX. and in which Today's patent-pending the share partner sampling market billion our as is billion and dairy $XX begun over Biftex and and preferences market and projected XXXX soon animal-free to recombinant their outside medium recombinant of sales. nonanimal dairy offer believe we culture growth as we'll driven
was school with of develop less current expertise microbial large producing than this established high cost-effective cost using dairy, the We're of which our expression recombinant Despite alliance our our dairy in enzymes platforms. off progress nonanimal to steady animal-free year ago. with proteins quantities a making partnership
longer-than-expected our we in this dairy While interested with food-grade to receive we In in also product alpha for now in delay companies with success quarter, protein of albumin met believe in albumin alternative agreement and this in year. validation, product. the $XXX,XXX X product. active due of second company a we a fourth We're create development commercializing XX joint this fee has a quarter alpha-lacta other nonexclusive project have non-animal to global in discussions a a the dairy top Lacta interest a encountered earnings our to success targets a expect resulted
beta-lactoglobulin To further dairy are to nonanimal in our sampling expand we the we markets. -- plan competitive pipeline, begin
goal grade quarter. the development develop in third in [indiscernible] agreement We are the the with and ongoing commercialization recombinant food a discussions to finalizing of product
bioindustrial refining. In bio last enzyme have for undergoing have actively with the we year, and customers. including we successfully cellulosic potential by partnership Farmbox, been several enzymes applications grade with across developing Over a biofuels multiple the industry nutrition, testing a developed biofuel industries,
promising the and well. created pulp targeted with biogas industry the for paper sectors Additionally, as and Dyadic use potential biofuel in at enzymes has initially
which to XX Our we in goal next these future. the is growth believe products in within commercializing months will drive revenue be the
to committed for human produced has segments. near-term completion first interest our nonprofit academia, is animal segment protein government, of and remain alternative of primary Phase the successful CX long-term revenue, growth significant health for deeply and we study from generated I organizations. focus industry in-human and potential pharmaceutical The our protein While the
of year, programs XX further of funded X complex produce and range including These cover and with Dyadic the top companies. showcase fully molecules. to projects, Since both standard wide antibody ability the human health initiated over and we've beginning XX funded disease third-party vaccine pharmaceutical a areas
disease parasitic CX HIV, HPV, multiple has diseases. including RSV Plasmodium platform Our vaccine antigens potential antigens, infectious and successfully expressed for several those
in antibodies, or for as delivered with infectious expressed company. evaluation second Additionally, more monoclonal mAbs which pharmaceutical Dyadic disease agents our for development, X is of top the in X quarter, X successfully MABs, neutralizing for XX
influenza U.S. In [indiscernible] its a influenza affecting use avian candidate's spread developed the interest ferritin been reported dairy provided nanoparticle or and ] assess to flu in and both Vertonnanoparticle potential vaccine an workers. outlook HX and continues in to to for companies, the the assessment [ among and poultry antibodies recent cattle well Birdflu, highlighting globally, candidate, avian human Dyadic with Cloud other cases collaboration the independent of birds, a neutralizing adjuvanted has from as The bird on or cows, possibly strong strength HX Virovax the vaccine especially X.X.X.X.B, human manufacturing as As animals. HX humans initial ] generate expert human a pharmaceutical commissioned studies wild and bird poultry, dairy platform poultry [ response, vaccine flu there positive animal vaccine growing U.S. even animal expert CX in LLC. with the
of antigen single-step additional are presented White fartinanoparticle and House and government NIH currently the several production week. novel antigen and Two adjuvant. AB Preparedness patients candidate HX including testing our been and Virovax Ferte bird CX demonstrated The human an HX vaccine Earlier in nanoparticle recombinant candidate flu the influenza quarter, bird potential response protein second vaccine in animal Office immune static [indiscernible], U.S. has to next a or government scheduled This robust Response promising preclinical candidate flu Pandemic with Veravax' agencies, combines announced policy. rabbits. for which for Dyadic
use indicate or Furthermore, the studies bird HX [ the produced We're further evaluation. high actively health X levels the veritonanoparticle flu, neutralizing against far circulating for the and vaccine sector interest cattle animal in ] has to initial providing preclinical as flu nanoparticle flu reduced avian animal samples vaccine ongoing the outbreak. generates various influenza the particularly animal to that bird bird pharmaceutical primary in recombinant combat viruses. influenza human increased antigen antibodies This of the candidate a CX for avian to potential in poultry of companies vaccine
initially efforts and over progress CFO, revenue we Alongside Health, alternative vaccines protein by evaluating in opportunities segment heightened Health in outbreak value with rigor, expertise. mid- intensifying flu capture the growth preparedness. development cover Animal on the response expansion on pandemic laser-focused Dyadic health, We're Ping on to product to with our and business brought Rawson, the awareness technology financial value human markets. partnership fully Animal to the our committed remain With a Fiber the in capitalizing by I'll for call Ping? animal turn while and animal the building segment health [indiscernible]. our and recombinant simultaneously near-term the that, driving protein our continued of We in bird focusing of we're ensuring long-term to
